Search results for "CAG"

showing 10 items of 492 documents

Optical release of caged glutamate for stimulation of neurons in the in vitro slice preparation

2005

Optical stimulation techniques prove useful to map func- tional inputs in the in vitro brain slice preparation: Glutamate released by a focused beam of UV light induces action potentials, which can be detected in postsynaptic neurons. The direct activation effect is influenced by factors such as compound concentration, focus depth, light absorption in the tissue, and sensitivity of different neuronal do- mains. We analyze information derived from direct stimulation ex- periments in slices from rat barrel cortex and construct a computa- tional model of a layer V pyramidal neuron that reproduces the experimental findings. The model predictions concerning the influ- ence of focus depth on inpu…

MalePatch-Clamp TechniquesUltraviolet RaysModels NeurologicalBiomedical EngineeringAction PotentialsStimulationIn Vitro TechniquesCaged glutamateBrain mappingBiomaterialsOpticsSlice preparationGlutamatesPostsynaptic potentialmedicineAnimalsComputer SimulationRats WistarMicroscopy VideoPhotolysisbusiness.industryChemistryPyramidal CellsGlutamate receptorEquipment DesignSomatosensory CortexBarrel cortexAtomic and Molecular Physics and OpticsRatsElectronic Optical and Magnetic Materialsmedicine.anatomical_structureLens (anatomy)SynapsesBiophysicsbusinessJournal of Biomedical Optics
researchProduct

Therapy and prognosis of extraoral malignant melanoma metastasizing to the jaw: case report and literature review.

2009

t a d With approximately 75% of all skin cancer-related deaths, malignant melanoma (MM) is the most lethal among common skin cancers, mostly because of its disposition to early lymphogenic and hematogenic metastasis. If a MM is diagnosed early, the overall prognosis is excellent, but once metastasized it becomes an incurable disease with high mortality. Prognosis is dependent on parameters such as gender, anatomic location, level of invasion, thickness, type of primary tumor, ulceration, and number and status of regional lymphatic nodes. For incidence and mortalty, a decrease in young but an increase in older roups—with geographic differences—has been reported. Because of the embryologic or…

MalePathologymedicine.medical_specialtySkin NeoplasmsMandibleMetastasisFatal OutcomemedicineHumansMelanomaPelvisAgedRib cagebusiness.industryBrain NeoplasmsMelanomaMandibleMandibular Prosthesis ImplantationPlastic Surgery Proceduresmedicine.diseasePrognosisPrimary tumorOsteotomySkullMandibular Neoplasmsmedicine.anatomical_structureOtorhinolaryngologySurgeryOral SurgerybusinessRare diseaseJournal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
researchProduct

Reconstruction with a pectoralis major myocutaneous flap after left first rib and clavicular chest wall resection for a metastasis from laryngeal can…

2016

We presented a case of recurrent metastasis from epidermoid cancer that occurred in the left clavicle of a patient with a history of laryngeal cancer treated on April 2005 with extended hemilaryngectomy, neck dissection and chemoradiation therapy. On September 2008, he developed a left clavicular metastasis. The disease was initially well controlled by chemoradiotherapy but it recurred 17 months later. The optimal treatment plan was established by several multidisciplinary meetings and the patient subsequently underwent an en bloc resection of the left clavicle, first rib and all the other involved structures. Coverage of the thoracic defect was achieved using pectoralis major myocutaneous …

MalePulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.medical_treatmentSettore MED/21 - Chirurgia ToracicaBone NeoplasmsRibsClavicular resection030204 cardiovascular system & hematologyMetastasisHemilaryngectomy03 medical and health sciences0302 clinical medicineChest wall involvementLaryngeal cancermedicineHumansThoracoplastyNeoplasm MetastasisThoracic WallLaryngeal NeoplasmsRib cagebusiness.industryBone metastasisCancerNeck dissectionGeneral MedicineMiddle AgedPlastic Surgery ProceduresMuscle flapmedicine.diseaseClavicleMyocutaneous FlapSurgerySettore MED/18 - Chirurgia GeneraleCardiothoracic surgeryChest wall involvement; Chest wall reconstruction; Clavicular resection; Laryngeal cancer; Muscle flap; Surgery; Pulmonary and Respiratory Medicine; Cardiology and Cardiovascular MedicineCarcinoma Squamous CellSurgeryNeoplasm Recurrence LocalbusinessChest wall reconstructionCardiology and Cardiovascular Medicine030217 neurology & neurosurgeryChemoradiotherapy
researchProduct

Liraglutide and Renal Outcomes in Type 2 Diabetes.

2017

BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a co…

MaleSettore MED/09 - Medicina InternaAcute Kidney Injury; Aged; Albuminuria; Creatinine; Diabetes Mellitus Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Kidney Failure Chronic; Liraglutide; Male; Middle AgedType 2 diabetes030204 cardiovascular system & hematologyurologic and male genital diseasesGLOMERULAR-FILTRATION-RATEKIDNEY-FUNCTIONDISEASElaw.inventionKidney Failurechemistry.chemical_compound0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawMedicineDiabetic NephropathiesHypoglycemic Agents.Settore MED/49 - Scienze Tecniche Dietetiche ApplicateChronicRISKKidneyAcute kidney injury11 Medical And Health SciencesGeneral MedicineAcute Kidney InjuryMiddle AgedIntention to Treat Analysismedicine.anatomical_structureCreatinineTRIALFemaleliraglutide randomized controlled trial type 2 diabetes renal outcomesLife Sciences & BiomedicineType 2Glomerular Filtration Ratemedicine.drugmedicine.medical_specialtyRenal function030209 endocrinology & metabolismCARDIOVASCULAR OUTCOMESFollow-Up Studie03 medical and health sciencesMedicine General & InternalDouble-Blind MethodGeneral & Internal MedicineDiabetes mellitusInternal medicineDiabetes MellitusAlbuminuriaHumansHypoglycemic AgentsIntensive care medicineAgedCreatinineScience & Technologybusiness.industryLiraglutideMORTALITYLiraglutidemedicine.diseaseINTENSIVE GLUCOSE CONTROLINDIVIDUALSDiabetes Mellitus Type 2chemistryDiabetic NephropathieKidney Failure ChronicLEADER Steering Committee and InvestigatorsbusinessFollow-Up Studies
researchProduct

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

2019

OBJECTIVE Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral semaglutide and the sodium–glucose cotransporter 2 inhibitor empagliflozin were compared in patients with type 2 diabetes uncontrolled on metformin. RESEARCH DESIGN AND METHODS Patients were randomized to once-daily open-label treatment with oral semaglutide 14 mg (n = 412) or empagliflozin 25 mg (n = 410) in a 52-week trial. Key end points were change from baseline to week 26 in HbA1c (primary) and body weight (confirmatory secondary). Two estimands addressed efficacy-related questions: treatment policy (regardless of trial product discontinuation or rescue medication) and trial product (on trial product with…

MaleSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismGlucagon-Like PeptidesAdministration OralType 2 diabeteslaw.inventionSettore MED/13 - Endocrinologia0302 clinical medicineGlucosidesRandomized controlled triallaw030212 general & internal medicineSettore MED/49 - Scienze Tecniche Dietetiche ApplicateBenzhydryl CompoundMiddle AgedMetforminMetforminTreatment Outcomediabetes mellitusDrug Therapy CombinationFemalemedicine.drugHumanAdultmedicine.medical_specialtyGlucagon-Like PeptideGlucosideUrology030209 endocrinology & metabolism03 medical and health sciencesPharmacotherapyDouble-Blind MethodWeight Loss.Diabetes mellitusWeight LossInternal MedicinemedicineEmpagliflozinHumansHypoglycemic AgentsBenzhydryl CompoundsGlycated HemoglobinAdvanced and Specialized NursingHypoglycemic Agentbusiness.industrySemaglutidemedicine.diseaseDiscontinuationDiabetes Mellitus Type 2business
researchProduct

Effect of Thyroid Hormones on Urea Biosynthesis and Related Processes in Rat Liver*

1988

The results of the few studies on the effect of the thyroid status on nitrogen metabolism have been inconclusive and/or contradictory. In an attempt to elucidate this important relationship, we have studied the effect of experimental hypo- and hyperthyroidism on urea biosynthesis and related processes. We have found that the capacity of the liver to synthesize urea was increased in hypothyroid rats, as were the activities of the urea cycle enzymes; there were also changes in the activities of some related enzymes and in the levels of intermediates and amino acids. Isolated hepatocytes from these rats showed an increased capacity for urea synthesis. In hyperthyroid rats the picture was more …

MaleThyroid Hormonesendocrine systemmedicine.medical_specialtyendocrine system diseasesCarbamoyl-Phosphate Synthase (Ammonia)HyperthyroidismIodide PeroxidaseGlucagonchemistry.chemical_compoundEndocrinologyGlutamatesHypothyroidismBiosynthesisAmmoniaInternal medicineCyclic AMPmedicineAnimalsUreaAmino AcidsOrnithine Carbamoyltransferasechemistry.chemical_classificationCatabolismRats Inbred StrainsMetabolismGlucagonRatsAmino acidThyroxineEndocrinologymedicine.anatomical_structureLiverchemistryBiochemistryUrea cycleHepatocyteUreaTriiodothyroninehormones hormone substitutes and hormone antagonistsEndocrinology
researchProduct

A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian …

2022

Background: Oral activated factor XI (FXIa) inhibitors may modulate coagulation to prevent thromboembolic events without substantially increasing bleeding. We explored the pharmacodynamics, safety, and efficacy of the oral FXIa inhibitor asundexian for secondary prevention after acute myocardial infarction (MI). Methods: We randomized 1601 patients with recent acute MI to oral asundexian 10, 20, or 50 mg or placebo once daily for 6 to 12 months in a double-blind, placebo-controlled, phase 2, dose-ranging trial. Patients were randomized within 5 days of their qualifying MI and received dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor. The effect of asundexian on FXIa inhibition…

MaleTicagrelorAspirinMyocardial InfarctionAnticoagulantsHemorrhageFactor XIaPercutaneous Coronary InterventionTreatment OutcomeDouble-Blind MethodPhysiology (medical)HumansFemale03.02. Klinikai orvostanAcute Coronary SyndromeCardiology and Cardiovascular MedicinePrasugrel HydrochloridePlatelet Aggregation InhibitorsAgedCirculation
researchProduct

Do randomized clinical trial selection criteria reflect levels of risk as observed in a general population of acute myocardial infarction survivors? …

2016

IF 4.638; International audience; Background: Few clinical trials have focused on populations with a history of distant myocardial infarction (MI). The PEGASUS trial assessed the impact of dual antiplatelet therapy in such patients, selected by enrichment criteria of high cardiovascular risk. Whether the PEGASUS population reflects the risk of a broader post-MI population is questionable. We analyzed whether 4-year mortality of a routine-practice population would differ according to the inclusion and exclusion criteria used in PEGASUS.Methods: FAST-MI is a nationwide French registry recruiting acute MI patients in November 2005; 2490 patients alive and without recurrent MI at one year were …

MaleTicagrelorMyocardial Infarction030204 cardiovascular system & hematologyCoronary artery diseaselaw.inventionCoronary artery disease0302 clinical medicineRandomized controlled trialRisk FactorslawSecondary PreventionRegistriesSurvivors030212 general & internal medicineMyocardial infarctionRandomized Controlled Trials as TopicAged 80 and overeducation.field_of_studyReperfusion therapyEvidence-Based PharmacotherapyMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemST-elevation myocardial infarctionPopulation SurveillanceInclusion and exclusion criteriaFemaleFranceAtherothrombotic EventsCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyPopulationAcute St-ElevationAcute myocardial infarctionVorapaxar03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineHumansMortalityeducationSelection (genetic algorithm)AgedAspirinbusiness.industryPatient SelectionAntiplatelet therapymedicine.diseaseComorbidityClinical trialAdherencePhysical therapyTherapybusinessFollow-Up Studies
researchProduct

Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute co…

2020

Abstract Aims In a randomized, parallel, blinded study, we investigate the impact of clopidogrel, prasugrel, or ticagrelor on peripheral endothelial function in patients undergoing stenting for an acute coronary syndrome. Methods and results The primary endpoint of the study was the change in endothelium-dependent flow-mediated dilation (FMD) following stenting. A total of 90 patients (age 62 ± 9 years, 81 males, 22 diabetics, 49 non-ST elevation myocardial infarctions) were enrolled. There were no significant differences among groups in any clinical parameter. Acutely before stenting, all three drugs improved FMD without differences between groups (P = 0.73). Stenting blunted FMD in the cl…

MaleTicagrelormedicine.medical_specialtyAcute coronary syndromeAdenosinePrasugrelmedicine.medical_treatment030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineInternal medicineClinical endpointHumansMedicineEndotheliumcardiovascular diseases030212 general & internal medicineAcute Coronary SyndromeAgedbusiness.industryStentMiddle Agedmedicine.diseaseClopidogrelCoronary VesselsThrombosisConfidence intervalClopidogrelTreatment OutcomePurinergic P2Y Receptor AntagonistsCardiologyFemaleCardiology and Cardiovascular MedicinebusinessPrasugrel HydrochlorideTicagrelorPlatelet Aggregation Inhibitorsmedicine.drugEuropean Heart Journal
researchProduct

Can new generation P2Y12 inhibitors play a role in microvascular obstruction in STEMI?

2016

MaleTicagrelormedicine.medical_specialtyAdenosinePrasugrel030204 cardiovascular system & hematologySTEMI03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineP2Y12Internal medicinemedicineHumans030212 general & internal medicineAgedbusiness.industryMiddle AgedMagnetic Resonance ImagingMicrovesselsPurinergic P2Y Receptor AntagonistsCardiologyST Elevation Myocardial InfarctionMVOFemaleCardiology and Cardiovascular MedicinebusinessPrasugrelPrasugrel HydrochlorideTicagrelorPlatelet Aggregation InhibitorsMRImedicine.drugInternational Journal of Cardiology
researchProduct